CA2694389C - Treatment of pediatric tumors - Google Patents

Treatment of pediatric tumors Download PDF

Info

Publication number
CA2694389C
CA2694389C CA2694389A CA2694389A CA2694389C CA 2694389 C CA2694389 C CA 2694389C CA 2694389 A CA2694389 A CA 2694389A CA 2694389 A CA2694389 A CA 2694389A CA 2694389 C CA2694389 C CA 2694389C
Authority
CA
Canada
Prior art keywords
tumor
treatment
tumors
pediatric
hydrogen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CA2694389A
Other languages
English (en)
French (fr)
Other versions
CA2694389A1 (en
Inventor
Claudio Pisano
Loredana Vesci
Paolo Carminati
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sigma Tau Industrie Farmaceutiche Riunite SpA
Original Assignee
Sigma Tau Industrie Farmaceutiche Riunite SpA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sigma Tau Industrie Farmaceutiche Riunite SpA filed Critical Sigma Tau Industrie Farmaceutiche Riunite SpA
Publication of CA2694389A1 publication Critical patent/CA2694389A1/en
Application granted granted Critical
Publication of CA2694389C publication Critical patent/CA2694389C/en
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
CA2694389A 2007-08-01 2008-07-03 Treatment of pediatric tumors Expired - Fee Related CA2694389C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP07113603.0 2007-08-01
EP07113603 2007-08-01
PCT/EP2008/058601 WO2009015981A2 (en) 2007-08-01 2008-07-03 Treatment of pediatric tumors

Publications (2)

Publication Number Publication Date
CA2694389A1 CA2694389A1 (en) 2009-02-05
CA2694389C true CA2694389C (en) 2016-01-19

Family

ID=38799381

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2694389A Expired - Fee Related CA2694389C (en) 2007-08-01 2008-07-03 Treatment of pediatric tumors

Country Status (11)

Country Link
US (1) US8829021B2 (enExample)
EP (1) EP2182951A2 (enExample)
JP (2) JP5765937B2 (enExample)
KR (1) KR20100051837A (enExample)
CN (1) CN101784277A (enExample)
BR (1) BRPI0815051A2 (enExample)
CA (1) CA2694389C (enExample)
EA (1) EA015933B1 (enExample)
MX (1) MX2010001084A (enExample)
SG (1) SG183010A1 (enExample)
WO (1) WO2009015981A2 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2889711A1 (en) 2012-10-29 2014-05-08 Arizona Board Of Regents On Behalf Of University Of Arizona Predictive markers for polyamine inhibitor cancer therapies
US10655183B2 (en) 2014-06-18 2020-05-19 Arizona Board Of Regents On Behalf Of University Of Arizona Carcinoma diagnosis and treatment based on ODC1 genotype
HK1248133A1 (zh) * 2015-02-12 2018-10-12 The Arizona Board Of Regents On Behalf Of The University Of Arizona 治疗神经母细胞瘤的方法
MA43114A (fr) 2015-10-30 2018-09-05 Cancer Prevention Pharmaceuticals Inc Formulation combinée à dose fixe d'éflornithine et sulindac
US10945981B2 (en) 2019-05-17 2021-03-16 Cancer Prevention Pharmaceuticals, Inc. Methods for treating familial adenomatous polyposis

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT1044977E (pt) 1999-03-09 2002-09-30 Sigma Tau Ind Farmaceuti Derivados de camptotecina com actividade antitumoral
BRPI0620209A2 (pt) 2005-12-21 2011-11-01 Sigma Tau Ind Famaceutiche Riunite S P A tratamento de tumores resistentes a fármacos
WO2008098701A1 (en) 2007-02-13 2008-08-21 Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. Broad-spectrum anti-cancer treatment based on iminocamptothecin derivatives

Also Published As

Publication number Publication date
WO2009015981A2 (en) 2009-02-05
KR20100051837A (ko) 2010-05-18
AU2008282024A1 (en) 2009-02-05
MX2010001084A (es) 2010-03-25
EP2182951A2 (en) 2010-05-12
US8829021B2 (en) 2014-09-09
WO2009015981A3 (en) 2009-09-03
JP2014111653A (ja) 2014-06-19
EA201070193A1 (ru) 2010-06-30
EA015933B1 (ru) 2011-12-30
US20100197718A1 (en) 2010-08-05
CA2694389A1 (en) 2009-02-05
BRPI0815051A2 (pt) 2015-02-10
SG183010A1 (en) 2012-08-30
JP2010534699A (ja) 2010-11-11
JP5765937B2 (ja) 2015-08-19
CN101784277A (zh) 2010-07-21

Similar Documents

Publication Publication Date Title
US9597325B2 (en) Inhibitors of late SV40 factor (LSF) as cancer chemotherapeutics
JP6090836B2 (ja) 化学療法剤の抗腫瘍活性増強剤
WO2004080462A1 (ja) c-Kitキナーゼ阻害剤
CA2694389C (en) Treatment of pediatric tumors
WO2017216257A1 (en) Cancer treatment by simultaneous targeting energy metabolism and intracellular ph
Lin et al. 4 (1H)-quinolone derivatives overcome acquired resistance to anti-microtubule agents by targeting the colchicine site of β-tubulin
JP2015214579A (ja) 癌細胞アポトーシス
JP2024513966A (ja) 肺がん及び非小細胞肺がんを処置する方法
US20220047573A1 (en) Methods for treating vascular malformations
JP2012012305A (ja) 抗がん剤の作用増強剤
CN109152766A (zh) 用于增殖性疾病的组合疗法
CN111132672A (zh) 抗药性胶质瘤的治疗
AU2008282024B2 (en) Treatment of pediatric tumors
Gao et al. Effects of Isoflurane on the Cell Pyroptosis in the Lung Cancer Through the HMGB1/RAGE Pathway
US8853233B2 (en) Broad-spectrum anti-cancer treatment based on iminocamptothecin derivatives
EP4041227A1 (en) A novel nanotechnologic approach to glioblastoma treatment with solid lipid carriers
EP4013417A1 (en) Methods and compositions for treating vascular malformations
CA2673869A1 (en) Method of treating multidrug resistant cancers
KR102740381B1 (ko) 벤즈이미다졸 유도체를 유효성분으로 함유하는 암 예방 또는 치료용 약학적 조성물
HK1142810A (en) Treatment of pediatric tumors
EP3893861A1 (en) Treatment and prevention of glioblastoma
Ramachandran Repurposing pimavanserin, an antipsychotic drug for pancreatic cancer and medulloblastoma treatment
HK40004682A (en) Magnesium theorate for treating tumors and compositions thereof
AU2005321960A1 (en) Method of treating cancer

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20130621

MKLA Lapsed

Effective date: 20170704